X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/25/2851479/0/en/BeyondSpring-Announces-First-Patient-Dosed-with-Pembrolizumab-Plinabulin-Plus-Etoposide-Platinum-in-a-Phase-2-Investigator-initiated-Study-of-First-Line-Extensive-Stage-Small-Cell-.html
https://www.globenewswire.com//news-release/2024/02/26/2835088/0/en/BeyondSpring-Regains-Compliance-with-Nasdaq-Minimum-Bid-Price-and-Periodic-Filing-Requirements.html
https://www.globenewswire.com//news-release/2024/01/10/2807447/0/en/BeyondSpring-Receives-Nasdaq-Delinquency-Notice-Regarding-Late-Filing-of-Its-Form-6-K.html
https://www.globenewswire.com//news-release/2023/12/18/2798154/0/en/BeyondSpring-Receives-Nasdaq-Notice-Regarding-Minimum-Bid-Price-Requirements.html
https://www.globenewswire.com//news-release/2023/11/07/2774892/0/en/BeyondSpring-Presents-Poster-Highlighting-Preclinical-and-Clinical-POC-Immunomodulating-Activity-of-Plinabulin-Inducing-Dendritic-Cell-Maturation-and-Re-sensitization-in-Immunother.html
https://www.globenewswire.com//news-release/2023/10/31/2770116/0/en/BeyondSpring-and-Professor-K-Eisenmann-of-the-University-of-Toledo-College-of-Medicine-Present-Poster-Highlighting-Plinabulin-s-Anti-cancer-Efficacy-in-Primary-and-Recurrent-Gliobl.html
https://www.globenewswire.com//news-release/2023/10/30/2769168/0/en/BeyondSpring-Regains-Compliance-with-Nasdaq-Minimum-Bid-Price-Requirement.html
https://www.globenewswire.com//news-release/2023/10/23/2764632/0/en/SEED-Therapeutics-a-BeyondSpring-Subsidiary-Appoints-Mr-Ko-Yung-Tung-to-the-Board-of-Directors.html
https://www.globenewswire.com//news-release/2023/10/04/2754923/0/en/BeyondSpring-Receives-Nasdaq-Notice-Regarding-Minimum-Bid-Price-Requirements.html
https://www.globenewswire.com//news-release/2023/09/27/2750534/0/en/BeyondSpring-and-Leading-Cancer-Center-to-Present-Poster-at-SITC-s-38th-Annual-Meeting.html
Market Place
Share 
